Recognition marker for intrahepatic cholangiocarcinoma carrying FGFR2 fusion or rearrangement
Through the morphological characteristics of HE stained images and artificial intelligence recognition technology, the sensitivity and cost problems of FGFR2 fusion/rearrangement detection are solved, and efficient and economical detection is achieved, which is suitable for clinical diagnosis in grassroots hospitals.
Patent Information
- Application Number
- CN202411087314.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
The existing FGFR2 fusion/rearrangement detection technology has problems such as limited sensitivity and specificity, high cost, complex data analysis, high sample processing requirements, technical limitations and long time consumption, which especially pose challenges to the clinical diagnosis of grassroots hospitals.
Based on the morphological characteristics of HE-stained images, a new FGFR2 fusion or rearrangement detection method was developed, and a mathematical model was established using artificial intelligence image recognition technology. Combined with the observation of pathologists, positive and negative ICCs of FGFR2 fusion/rearrangement were screened out. In case, kits and HE staining reagents are provided to simplify the detection process.
It realizes efficient, reliable and economical FGFR2 fusion/rearrangement testing, significantly saves time and economic costs, reduces technical thresholds, and is suitable for clinical diagnosis in grassroots hospitals.
Smart Images

Figure BDA0004985530700000081 
Figure BDA0004985530700000091 
Figure BDA0004985530700000101
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of clinical medical diagnostic tools, and specifically relates to an identification marker for intrahepatic cholangiocarcinoma carrying FGFR2 fusion or rearrangement, the application of the identification marker in the preparation of an FGFR2 fusion / rearrangement positive ICC detection reagent, and also relates to a kit for detecting FGFR2 fusion / rearrangement positive ICC. Background Art
[0002] Intrahepatic cholangiocarcinoma (ICC or iCCA) refers to adenocarcinoma originating from the epithelium of the secondary bile duct and its branches. The incidence of FGFR2 (fibroblast growth factor receptor 2) fusion in ICC is 8.7-12.7% in European and American countries and 2-13% in China. FGFR2 fusion / rearrangement is an important molecular target for biliary malignancies. Based on the results of FIGHT202 and its Chinese bridging trial CIBI375A201, the US FDA and China NMPA approved pemigatinib on April 17, 2020 and March 29, 2022, respectively, for the treatment of patients with previously treated, unresectable advanced, metastatic cholangiocarcinoma carrying FGFR2 fusion or rearrangement. The NCCN Guidelines for Hepatobiliary Tumors and the CSCO Guidelines for the Diagnosis and Treatment of Biliary Malignancies also recommend this drug as a second-line treatment for patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement. Based on the results of FOENIX-CCA2, the US FDA granted accelerated approval to futibatinib for patients with previously treated, unresectable, locally advanced or metastatic ICC with FGFR2 gene fusion / rearrangement.
[0003] A variety of methods can be used to detect FGFR2 gene fusion / rearrangement in tissue samples, including immunohistochemistry (IHC), reverse transcription polymerase chain reaction (RT-PCR), in situ fluorescence hybridization (FISH), and DNA / RNA-based next-generation sequencing (NGS). However, for the identification of FGFR2 fusion / rearrangement, the sensitivity and specificity of the current IHC antibodies for FGFR2 fusion / rearrangement are limited, and more than 140 fusion partner genes have been found for FGFR2 fusion, except for the relatively common fusion partner gene BICC1, there is no hotspot fusion partner. Therefore, IHC and RT-PCR are not applicable. Common methods for FGFR2 fusion detection include FISH, DNA-NGS, and RNA-NGS. FGFR2 FISH detection mainly uses separation probes and can be applied to various types of samples, including tumor tissue sections, cell prints, etc., and has strong applicability. In addition, FISH has high sensitivity and can detect low copy number gene changes. However, both FISH and DNA-NGS are based on the DNA level, so it is impossible to determine whether the detected fusion will produce expressible fusion RNA (i.e., non-pathogenic fusion), resulting in a high false positive rate. In addition, FISH cannot identify partner genes and may miss intrachromosomal rearrangements with a shorter distance, resulting in false negatives. RNA-NGS can not only identify RNA breakpoints and detect new fusions, but also detect expression levels. It is currently the most effective and recommended method for FGFR2 fusion / rearrangement. However, molecular detection methods such as NGS and FISH have some additional disadvantages and limitations: (1) High cost: NGS technology requires expensive instruments and consumables, and data analysis and interpretation also require professionals, so the cost is high. Although FISH is relatively low in cost, it still requires expensive probes and microscope equipment. (2) Complex data analysis: The amount of data generated by NGS is huge, requiring complex data processing and analysis techniques, and there is a high technical threshold for data interpretation and result presentation. FISH analysis also requires professional knowledge and rich experience. (3) High sample processing requirements: NGS requires high sample quality and purity, and has strict requirements on the quality and concentration of DNA or RNA extraction. Sample processing may increase operational risks. FISH requires the use of appropriate cell or tissue samples and requires specific experimental operations. (4) Technical limitations: NGS technology may not be able to detect low-frequency mutations, and there may be errors and missed detections, especially for complex genomic structures. FISH technology is also subject to certain limitations, such as the need for precise probe design and specific conditions. (5) Time-consuming: In some cases, NGS or FISH analysis may take a long time to produce results, which may have a certain impact on clinical diagnosis or research progress. Especially for grassroots hospitals, the lack of an effective molecular detection platform makes it more challenging to identify ICC with FGFR2 fusion / rearrangement. Summary of the invention
[0004] In view of the above shortcomings of the existing ICC FGFR2 fusion / rearrangement detection technology, our research group has developed a new FGFR2 fusion or rearrangement detection method based on the tissue samples of intrahepatic cholangiocarcinoma patients collected by Zhongshan Hospital of Fudan University over the years and according to the morphological characteristics of ICC, which can efficiently and reliably screen ICC cases with FGFR2 fusion / rearrangement, significantly saving the time and economic costs brought by large-scale molecular testing. Based on this research result, the present invention includes the following technical solutions.
[0005] The first aspect of the present invention provides an identification mark for intrahepatic cholangiocarcinoma (ICC) carrying FGFR2 fusion or rearrangement, which is a HE staining (also known as H&E staining, HE staining, hematoxylin-eosin staining) image of a confirmed intrahepatic cholangiocarcinoma (ICC) tumor tissue and surrounding liver tissue sections. Based on the morphology of the HE staining image, the HE staining image (i) of the dysplastic plate malformation (DPM) type FGFR2 fusion or rearrangement positive ICC has the following morphological characteristics: the glandular cavity is irregularly cystic and dilated in varying sizes, and the lining epithelium protrudes into the cavity like polyps; the cancer cells are flat, small cubes or low columns, with clear and sparse cytoplasm, small and lightly stained nuclei, and lack of mucus secreting cells; the glandular ducts in the central area of the tumor are larger, the fibrous stroma is dense, and the glandular ducts in the peripheral area are smaller, with little invasion of blood vessels and nerve bundles; and there is no fatty degeneration in the surrounding liver tissue; or
[0006] HE staining images of FGFR2 fusion or rearrangement positive ICC of common small bile duct type ICC (ii) Morphological characteristics are: mostly arranged in dense and regular small glandular duct structures; mostly moderately to highly differentiated; cancer cells are cuboidal or low columnar, with little cytoplasm and lack of mucus secreting cells; fibrous stroma; rarely invade adjacent portal areas, blood vessels, lymphatic vessels and nerves; and there is no fatty degeneration in the surrounding liver tissue.
[0007] The above terms "big", "small", "high", "low", "more" and "less" are relative terms used in pathologist observation or artificial intelligence image recognition, and can be specifically defined in artificial intelligence image recognition.
[0008] In one embodiment, the above-mentioned ductal plate malformation (DPM) type FGFR2 fusion or rearrangement positive ICC image (i) is substantially as follows Figure 3-6 As shown in any one of Figure 3 and Figure 5 This is a 200-fold magnified image. Figure 4 and Figure 6 This is a 400-fold magnified image. Figure 3 and Figure 4 It's the same case. Figure 5 and Figure 6 It's the same case.
[0009] In another embodiment, the HE staining image (ii) of the FGFR2 fusion or rearrangement positive ICC of the conventional small bile duct type ICC is substantially as follows Figure 7 or Figure 8 As shown, Figure 7 and Figure 8 It's the same case. Figure 7 This is a 200-fold magnified image. Figure 8 This is a 400-fold magnified image.
[0010] Optionally, CLC is used as a negative reference for FGFR2 fusion or rearrangement, that is, CLC is basically a case of intrahepatic cholangiocarcinoma (ICC) that does not carry FGFR2 fusion or rearrangement. The morphological characteristics of CLC in the image (iii) are: small lumen, less than 15 μm in diameter; composed of small cubic cancer cells with little atypia, small ducts arranged in sparse branching, embedded in a hyalinized fibrous stroma, with little invasion of blood vessels and nerve bundles.
[0011] In one embodiment, the image (iii) of the cholangiocarcinoma (CLC) is substantially as follows Figure 1 or Figure 2 As shown, Figure 1 and Figure 2 It's the same case. Figure 1 This is a 200-fold magnified image. Figure 2 This is a 400-fold magnified image.
[0012] Furthermore, the HE-stained image of the intrahepatic cholangiocarcinoma (ICC) carrying FGFR2 fusion or rearrangement is an HE-stained image that does not contain a small cholangiocarcinoma (CLC) component and has no fatty degeneration in the surrounding liver (iv).
[0013] In one embodiment, the HE staining image (iv) of the peripheral liver without fatty degeneration is substantially as follows Fig. 9 or Fig.10 As shown, Fig. 9 and Fig.10 It's the same case. Fig. 9 This is a 200-fold magnified image. Fig.10 This is a 400-fold magnified image.
[0014] Optionally, the HE staining image of the bold cast type ICC (v) is used as a negative reference for FGFR2 fusion or rearrangement, that is, the bold cast type ICC is basically an intrahepatic cholangiocarcinoma (ICC) case that does not carry FGFR2 fusion or rearrangement. The HE staining image of the bold cast type ICC (iii) has the following morphological characteristics: arranged in irregular glandular tubules, mainly with moderate to poor differentiation; cancer cells are cuboidal or columnar; there are mucus-secreting cells or mucus in the lumen; significant desmoplastic stroma; common portal area, vascular, nerve invasion and lymph node metastasis.
[0015] In one embodiment, the HE staining image (iii) of the bold cast ICC is substantially as follows: Figure 11-13 Any one of the following is shown.
[0016] The second aspect of the present invention provides the use of the above-mentioned identification marker in the preparation of an FGFR2 fusion / rearrangement positive ICC detection reagent.
[0017] In one application, a mathematical model or image model for judging FGFR2 fusion / rearrangement negative and FGFR2 fusion / rearrangement positive can be established by artificial intelligence image recognition technology based on the above-mentioned identification marks, such as the morphological features of HE staining images (i) to (v), such as glandular duct structure, duct size, intracellular mucus, cell atypia, tumor stroma, nerve and vascular involvement status, etc. as variable factors.
[0018] The above mathematical model or image model can be input into a computer terminal or a detection and analysis device used for tumor sample detection or pathological analysis, so as to make timely judgments on the HE staining images of tissue samples.
[0019] The third aspect of the present invention provides a kit for detecting FGFR2 fusion / rearrangement positive ICC, which at least includes instructions recording the above-mentioned identification mark, namely the morphological characteristics of HE staining image.
[0020] Furthermore, the above-mentioned kit also includes the following substances: tissue fixative (such as 10% paraformaldehyde solution); ethanol and xylene for making tissue transparent; paraffin for embedding transparent tissue; eosin and hematoxylin for staining; neutral gum for sealing, and other HE staining reagents and additives.
[0021] The instructions may be written on bottles, test tubes and the like, boards, or on a separate piece of paper, or on the outside or inside of a container, such as a paper with an operation demonstration video APP download window such as a QR code. The instructions may also be in multimedia form, such as a CD, U disk, network disk, etc.
[0022] The present invention is based on the morphology of HE-stained images of tumor tissue and surrounding liver tissue sections of ICC patients. Based on the present invention, all patients with intrahepatic cholangiocarcinoma, including early-stage patients, can be extensively and effectively screened for cases with high suspicion of carrying pathogenic FGFR2 fusion / rearrangement through pathologist observation or artificial intelligence image recognition, thus having the advantages of being simple, rapid, efficient, easy to operate, low economic cost, and strong practicality. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 HE-stained photograph showing the morphology of cholangiocarcinoma (CLC), magnified 200 times.
[0024] Figure 2 To display Figure 1 HE-stained photograph showing the morphology of cholangiocarcinoma (CLC), magnified 400 times.
[0025] Figure 3 HE-stained photograph showing the morphology of a type of ICC with dysplastic plate malformation (DPM), magnified 200 times.
[0026] Figure 4 To display Figure 3 HE-stained photograph showing the morphology of ICC with dysplastic plate malformation (DPM) type, magnified 400 times.
[0027] Figure 5 HE-stained photograph showing the morphology of another type of ICC, dysplastic plate malformation (DPM), magnified 200 times.
[0028] Figure 6 To display Figure 5 HE-stained photograph showing the morphology of ICC with dysplastic plate malformation (DPM) type, magnified 400 times.
[0029] Figure 7 HE-stained photograph showing the morphology of common small bile duct ICC, magnified 200 times.
[0030] Figure 8 To display Figure 7 The HE-stained photograph of the morphology of common small bile duct ICC is shown, magnified 400 times.
[0031] Fig. 9 This is a HE-stained photograph of the morphology of peripheral liver tissue without fatty degeneration, magnified 200 times.
[0032] Fig.10 To display Fig. 9 HE-stained photograph showing the morphology of peripheral liver tissue without fatty degeneration, magnified 400 times.
[0033] Fig.11HE-stained photograph showing the morphology of bold cast ICC, magnified 200 times.
[0034] Fig.12 To display Fig.11 HE-stained photograph showing the morphology of bold cast ICC, magnified 400 times.
[0035] Fig.13 HE-stained photograph showing the spread of bold cast-type ICC tumors along the portal area, magnified 40 times. DETAILED DESCRIPTION
[0036] In the liver tissue, the intrahepatic bile duct system is composed of lining bile duct epithelial cells and their peribiliary glands, which branch out step by step to form large bile duct groups (regional bile duct-segmental bile duct, 300-800 μm) and small bile duct groups (Herling's duct-interlobular bile duct-septal bile duct, <300 μm), thus forming the anatomical basis for the histological classification of large bile duct type and small bile duct type ICC.
[0037] The World Health Organization has found that there are two major subtypes of ICC: the large bile duct type originating from bile duct epithelial cells near the liver hilum and the small bile duct type originating from peripheral bile duct epithelial cells. Further studies have confirmed that these two ICC subtypes have huge differences in terms of driver gene mutations, histological morphology, and clinical prognosis of patients, suggesting that molecular classification of ICC based on tumor origin is of great significance for personalized treatment of tumors. However, due to the lack of recognized oncological markers and the atypical histological morphology of a large proportion of ICC (about 32.4%), people's understanding of the origin of ICC has been affected and hindered.
[0038] On March 28, 2022, the research groups of Academician Fan Jia / Professor Gao Qiang from Zhongshan Hospital of Fudan University, Researcher Xi Ruibin from the School of Mathematical Sciences of Peking University, and Researcher Zhang Xiaoming from the Shanghai Pasteur Institute of the Chinese Academy of Sciences published a study titled "Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma" in Nature Communications. Based on single-cell transcriptome sequencing, the study found and identified specific tumor markers for large and small bile duct ICC, and revealed the differences between the two different ICC subtypes in clinical prognosis, tumor microenvironment characteristics, cell origin, etc., providing a theoretical basis for a deeper understanding of ICC tumor heterogeneity and its personalized precision treatment.
[0039] In our pathological study of intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement, we found that the HE staining images of tumor tissue and surrounding liver tissue of patients with FGFR2 fusion / rearrangement-positive ICC had specific morphological characteristics. Based on this morphological feature, it can help distinguish patients with FGFR2 fusion / rearrangement-positive ICC from ordinary patients with FGFR2 fusion / rearrangement-negative ICC. Choledocholangiocarcinoma (CLC) and dilated ductal malformation (DPM)-type ICC are two special types of small bile duct ICC. We further found that in cases of small bile duct ICC with pathogenic FGFR2 fusion / rearrangement, the tissue HE staining photos of ordinary ICC and dilated ductal malformation (DPM)-type ICC also have their own characteristics, so FGFR2 fusion / rearrangement-positive small bile duct ICC can be further subdivided.
[0040] Herein, the term "carrying FGFR2 fusion or rearrangement" may also be referred to as "FGFR2 fusion / rearrangement positive", especially referring to "small bile duct ICC with pathogenic FGFR2 fusion / rearrangement". Accordingly, the absence of FGFR2 fusion or rearrangement may be referred to as "FGFR2 fusion / rearrangement negative".
[0041] It is easy for a person skilled in the art to understand that standardizing the HE staining images of FGFR2 fusion / rearrangement negative ICC and FGFR2 fusion / rearrangement positive ICC tissue samples can greatly improve the efficiency and accuracy of pathological detection and analysis. The method of HE staining image standardization is to establish a mathematical model or image model that can basically distinguish between FGFR2 fusion / rearrangement negative and FGFR2 fusion / rearrangement positive, and input it into a computer and detection / reading equipment through a computer program, which can replace the experience judgment of experienced pathological analysis experts to a certain extent.
[0042] Similar image processing technology can be referred to the method disclosed in patent document CN110553883A. This method first groups the images of tissue sections into H&E stained tissue images and IHC stained tissue images, and then performs a cross-stained image registration and fusion process on the IHC stained tissue images and H&E stained tissue images of different groups to obtain multiple frames of cross-stained tissue images.
[0043] In the construction of the mathematical model or image model of the present invention, the model can be built based on HE-stained images (i) to (v) or more images of tissue samples that have been clearly distinguished as FGFR2 fusion / rearrangement-negative ICC and FGFR2 fusion / rearrangement-positive ICC cases by FISH and DNA-NGS detection based on DNA levels as training samples.
[0044] Optionally, the mathematical model or image model constructed above may further include RNA-NGS detection results, for example, further include detection data of the fusion partner BICC1.
[0045] It is well known in the medical field that HE staining is a relatively simple staining method that does not require complicated experimental conditions and equipment. Compared with molecular detection methods such as NGS and FISH, it has the advantages of low cost, fast speed, simple operation and analysis, and is suitable for staining of routine tissue sections.
[0046] It is easy for a person skilled in the art to understand that the implementation of the technical solution of the present invention, i.e., the operation of HE staining analysis of tissue sections, generally includes the following steps:
[0047] a. Sampling: Sampling the intrahepatic cholangiocarcinoma tumor and surrounding liver tissue to obtain tissue samples;
[0048] b. Tissue processing: tissue fixation, dehydration, embedding, sectioning, and H&E staining of tissue samples. When eosin is used to stain tissue, the cytoplasm is stained pink; hematoxylin stains the cell nucleus and intracellular ribosomes blue and purple.
[0049] c. Morphological analysis: Pathologists observe the morphological features under a microscope to screen small bile duct ICC cases that do not contain CLC components and have no fatty degeneration of the surrounding liver.
[0050] Through the above process, small bile duct ICC cases with pathogenic FGFR2 fusion / rearrangement can be efficiently screened, providing an important basis for personalized treatment and disease research. NGS can be performed on the screened cases to confirm whether there is ICC with pathogenic FGFR2 fusion / rearrangement.
[0051] We systematically analyzed the pathological specimens of 322 ICC patients who underwent surgical resection at Zhongshan Hospital of Fudan University between 2019 and 2022, and the tumor sections were re-evaluated by two experienced pathologists. From these, 226 cases with high tumor quality who did not receive preoperative chemoradiotherapy were selected for study. RNA-NGS was used to detect FGFR2 fusion / rearrangement. Clinical information of the 226 patients was collected, and their pathological characteristics were recorded. Combining RNA-NGS results with clinical pathological results, univariate analysis was used to analyze the clinicopathological characteristics of ICC cases with pathogenic FGFR2 rearrangement / fusion compared with ICC cases without pathogenic FGFR2 rearrangement / fusion. Based on HE morphology, ICC patients, including early patients, can be widely and effectively screened for cases with high suspicion of pathogenic FGFR2 fusion / rearrangement by pathologist observation or artificial intelligence image recognition.
[0052] By observing and analyzing the HE morphological characteristics of ICC, technicians in this field can screen ICC cases with FGFR2 fusion / rearrangement, which greatly saves the time and economic costs brought by large-scale molecular testing.
[0053] The present invention will be further described below in conjunction with specific embodiments and accompanying drawings. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0054] In the embodiments of the present invention, if there is no specific description on the experimental operation temperature, the temperature generally refers to room temperature (10-40° C.).
[0055] This article involves the addition amount, content and concentration of various substances, and the percentages mentioned therein, unless otherwise specified, are all percentages by weight.
[0056] Example 1: HE staining of tissue
[0057] Tumor and surrounding liver tissues of intrahepatic cholangiocarcinoma cases were fixed in tissue fixative (10% paraformaldehyde solution) for 24 hours. They were embedded in paraffin and then made into 5 μm thick horizontal sections. They were stained with HE and representative images under light microscope (magnified 200 times and 400 times, respectively) were selected for analysis.
[0058] The negative and positive images of FGFR2 fusion / rearrangement in ICC cases were examined by HE staining of paraffin sections as follows:
[0059] (1) Dewaxing: Dewaxing in xylene I and II for 10 minutes each. Prepare coverslips in advance.
[0060] (2) Cover with water, apply 100% (I, II), 90%, 80%, and 70% alcohol for 5 minutes each, and rinse with tap water for 5 minutes × 3.
[0061] (3) Stain with hematoxylin for 5 minutes. Depending on the staining situation, the staining time can be appropriately increased or decreased, and rinse with running water.
[0062] (4) Differentiate with 5% acetic acid for 1 minute, rinse with running water, and use a pipette to add acetic acid until it covers the entire tissue on the slide. After differentiation, the color becomes lighter and turns blue.
[0063] (5) Stain with eosin for 10 seconds. The staining time can be appropriately increased or decreased depending on the staining situation. After the staining is completed, the dye is recovered and rinsed with running water.
[0064] (6) Dehydration: 70%, 80%, 90%, and 100% alcohol for 10 seconds each, and xylene for 1 minute. The slides can be naturally dried in a fume hood and then sealed for about 5 minutes.
[0065] (7) Apply neutral gum and seal the slide. Use a pipette to apply one drop, as little as possible. However, after pressing the slide, make sure that the entire tissue is covered to avoid bubbles in the middle.
[0066] (8) Take bright-field photos under a microscope and select representative images for histological analysis. These images include: Figures 1 to 13 Images (i) to (v) shown.
[0067] Example 2: Case analysis statistics
[0068] We collected surgical specimens from 322 ICC patients who underwent surgical resection at Zhongshan Hospital of Fudan University between 2019 and 2022. Tumor sections were re-evaluated by two experienced pathologists. From these, 226 cases with high tumor quality who did not receive preoperative chemoradiotherapy were selected for study. RNA-NGS was used to detect FGFR2 fusion / rearrangement. Clinical information of the 226 patients was collected, and their pathological characteristics were recorded. Combining RNA-NGS results with clinical pathological results, univariate analysis was used to analyze the clinicopathological characteristics of ICC cases with pathogenic FGFR2 rearrangement / fusion compared with ICC cases without pathogenic FGFR2 rearrangement / fusion. Based on H&E morphology, ICC patients, including early patients, can be widely and effectively screened for cases with high suspicion of pathogenic FGFR2 fusion / rearrangement by pathologist observation or artificial intelligence image recognition.
[0069] Based on RNA-NGS results, 22 (9.7%) of 226 ICC cases were positive for FGFR2 fusion / rearrangement, of which 20 (20 / 22, 91%) had pathogenic FGFR2 fusion / rearrangement. BICC1 was the most common fusion partner.
[0070] In this cohort of 226 ICC patients, the median age was 65 years (range, 32-87 years), with a higher proportion of males (male:female = 3:2). Small bile duct ICC accounted for 58% (n = 132) of the cohort, and large bile duct ICC accounted for 42% (n = 94). Small bile duct carcinoma (CLC) and ductal plate malformation (DPM) ICC are two special types of small bile duct ICC. In this cohort, 33% (n = 43) of small bile duct ICC cases contained at least 10% DPM-type ICC components, while 19% (n = 25) of cases contained at least 10% CLC components. Among them, 8 cases had both DPM-type ICC and CLC components. Tables 1 and 2 summarize the clinicopathological features of ICC patients with FGFR2 rearrangement / fusion.
[0071] Clinical pathological analysis and univariate analysis showed that among the 20 ICC cases with pathogenic FGFR2 rearrangement / fusion, 85% (n=17) were small bile duct ICC (P=0.011). Compared with small bile duct ICC cases without pathogenic FGFR2 rearrangement / fusion, small bile duct ICC cases with pathogenic FGFR2 rearrangement / fusion often lacked CLC components (P=0.033) and were less likely to have fatty degeneration of the surrounding liver (P=0.003) (Table 2). Therefore, selecting small bile duct ICC without CLC components and fatty degeneration of the surrounding liver by H&E morphology can effectively screen ICC with pathogenic FGFR2 fusion / rearrangement.
[0072] Table 1. Clinicopathological characteristics of ICC patients with pathogenic FGFR2 fusions (N = 226)
[0073]
[0074]
[0075]
[0076]
[0077] Note: ICC stands for intrahepatic cholangiocarcinoma and MVI stands for microvascular invasion
[0078] Table 2. Clinicopathological features of small bile duct ICC with pathogenic FGFR2 fusion (N=132)
[0079]
[0080]
[0081]
[0082] Note: CLC stands for fine bile duct carcinoma, DPM stands for ductal plate malformation, ICC stands for intrahepatic bile duct carcinoma, and MVI stands for microvascular invasion Example 3: Image analysis statistics
[0083] Representative images include Figures 1 to 13 Images (i) to (v) shown.
[0084] Figure 1 and Figure 2 The morphological characteristics of cholangiocarcinoma (CLC) are shown: small lumen, diameter <15 μm; composed of small cubic cancer cells, with little atypia, small ducts arranged in sparse branching, embedded in hyaline degenerated fibrous stroma, with little invasion of blood vessels and nerve bundles.
[0085] Figure 3 , Figure 4 , Figure 5 and Figure 6 The morphological characteristics of DPM type ICC were shown: the glandular cavity was irregularly dilated in varying sizes, and the lining epithelium showed polyp-like protrusions into the cavity; the cancer cells were flat, small cubic or low columnar, with clear and sparse cytoplasm, small and lightly stained nuclei, and lack of mucus-secreting cells; the glandular ducts in the central area of the tumor were larger and the fibrous stroma was dense, while the glandular ducts in the peripheral area were smaller, with little invasion of blood vessels and nerve bundles.
[0086] Figure 7 , Figure 8 , Fig. 9 and Fig.10 The morphological characteristics of common small bile duct ICC were shown: mostly arranged in dense and relatively regular small glandular duct structures; mostly moderately to highly differentiated; cancer cells were cubic or low columnar, with little cytoplasm and lack of mucus-secreting cells; fibrous stroma; and less invasion of adjacent portal areas, blood vessels, lymphatic vessels and nerves.
[0087] Fig.11 , Fig.12 and Fig.13 The morphological characteristics of bold cast ICC are shown: arranged in irregular glandular tubules, mainly with moderate to poor differentiation; the cancer cells are cuboidal or columnar; there are mucus-secreting cells or mucus in the lumen; there is a significant desmoplastic stroma; and there is common invasion of portal areas, vessels, nerves, and lymph node metastasis.
[0088] The above embodiments are intended to facilitate the understanding and use of the present invention by those skilled in the art. It is obvious that those skilled in the art can easily make modifications to the embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments. Improvements and modifications made by those skilled in the art based on the principles of the present invention without departing from the scope of the present invention should be within the protection scope of the present invention.
Claims
1. A marker for intrahepatic cholangiocarcinoma carrying FGFR2 fusion or rearrangement, which is a HE-stained image of a confirmed intrahepatic cholangiocarcinoma tumor tissue and surrounding liver tissue sections. Based on the morphology of the HE-stained image, the HE-stained image of the bile duct plate abnormality type FGFR2 fusion or rearrangement positive ICC (i) has the following morphological characteristics: the glandular cavity is irregularly cystic and dilated in varying sizes, and the lining epithelium protrudes into the cavity like polyps; the cancer cells are flat, small cubic or low columnar, with clear and sparse cytoplasm, small and lightly stained nuclei, and lack of mucus secreting cells; the glandular ducts in the central area of the tumor are larger, with dense fibrous stroma, and the glandular ducts in the peripheral area are smaller, with little invasion of blood vessels and nerve bundles; and there is no fatty degeneration in the surrounding liver tissue; or HE staining images of FGFR2 fusion or rearrangement positive ICC of common small bile duct type ICC (ii) Morphological characteristics are: mostly arranged in dense and regular small glandular duct structures; mostly moderately to highly differentiated; cancer cells are cuboidal or low columnar, with little cytoplasm and lack of mucus secreting cells; fibrous stroma; rarely invade adjacent portal areas, blood vessels, lymphatic vessels and nerves; and there is no fatty degeneration in the surrounding liver tissue.
2. The identification mark according to claim 1, characterized in that: The bile duct plate malformation type FGFR2 fusion or rearrangement positive ICC image (i) is substantially as shown in any one of Figures 3-6, wherein Figures 3 and 5 are 200 times magnified images, and Figures 4 and 6 are 400 times magnified images. Figures 3 and 4 are the same case, and Figures 5 and 6 are the same case; The HE staining image (ii) of FGFR2 fusion or rearrangement-positive ICC of common small bile duct type ICC is basically as shown in FIG. 7 or FIG. 8 . FIG. 7 and FIG. 8 are the same case, FIG. 7 is a 200-fold magnification image, and FIG. 8 is a 400-fold magnification image.
3. The identification mark according to claim 1, characterized in that: Cholangiocarcinoma is used as a negative reference for FGFR2 fusion or rearrangement. The morphological characteristics of cholangiocarcinoma in the image (iii) are as follows: small lumen, less than 15 μm in diameter; composed of small cuboidal cancer cells with little atypia, small ducts arranged in sparse branching patterns, embedded in a hyaline, degenerated fibrous stroma, with little invasion of blood vessels and nerve bundles.
4. The identification mark according to claim 3, characterized in that: The image of bile duct carcinoma (iii) is basically as shown in FIG. 1 or FIG. 2 . FIG. 1 and FIG. 2 are of the same case. FIG. 1 is a 200-fold magnified image, and FIG. 2 is a 400-fold magnified image.
5. The identification mark according to claim 4, characterized in that: The HE-stained image of intrahepatic cholangiocarcinoma carrying FGFR2 fusion or rearrangement is an HE-stained image that does not contain bile duct carcinoma and has no fatty degeneration in the surrounding liver (iv).
6. The identification mark according to claim 5, characterized in that: The HE-stained image (iv) of the peripheral liver without fatty degeneration is basically as shown in FIG. 9 or FIG. 10 . FIG. 9 and FIG. 10 are for the same case, FIG. 9 is a 200-fold magnified image, and FIG. 10 is a 400-fold magnified image.
7. The identification mark according to claim 1, characterized in that: HE staining image of bold cast ICC (v) is used as a negative reference for FGFR2 fusion or rearrangement. HE staining image of bold cast ICC (iii) has the following morphological characteristics: arranged in irregular glandular tubules, mainly moderate to poor differentiation; cancer cells are cuboidal or columnar; there are mucus-secreting cells or mucus in the lumen; significant desmoplastic stroma; common portal areas, vascular and neural invasion and lymph node metastasis.
8. The identification mark according to claim 6, characterized in that: The HE-stained image of the large bold cast ICC (iii) is substantially as shown in any one of FIGS. 10-13 .
9. Use of the identification marker according to any one of claims 1 to 8 in the preparation of a FGFR2 fusion / rearrangement positive ICC detection reagent.
10. A kit for detecting FGFR2 fusion / rearrangement positive ICC, characterized in that: The invention at least comprises a description recording the morphological characteristics of the identification mark, i.e., the HE staining image, as described in any one of claims 1 to 8.
